The core policy problem
A low-cost prescription is not good value if it cannot be tolerated, used consistently, or matched to documented need. The policy question is what happens after standard first-line options fail.
Briefing note
For MPs and decision-makers
This page gives parliamentary offices, councillors, and decision-makers a concise policy frame for constituents who report repeated eczema prescribing failure.
One-paragraph issue
When first-line emollients are unsuitable or ineffective for a patient, prescribing based only on unit cost can become a false economy. The campaign asks for clearer review routes after documented failure and better evidence on total eczema care cost.
Briefing summary
A public briefing for MPs, journalists, charities, and NHS stakeholders.
For scrutiny, policy engagement, or media enquiries, use the monitored campaign contact route.
Campaign ask
Smarter Eczema Prescribing is a public-interest campaign asking whether NHS eczema prescribing gives primary care a clear route to clinically suitable alternatives after documented first-line emollient failure. It argues that prescribing policy should consider suitability, acceptability, and total care cost, not only the unit cost of a tube.
The five policy asks
- Recognise documented emollient failure as a reason to review prescribing options.
- Give GPs clearer routes to prescribe clinically suitable alternatives when formulary options fail.
- Assess eczema prescribing by total care cost, not only unit product cost.
- Review whether selected fragrance-free, paraffin-free, or otherwise clinically appropriate alternatives should be available for documented need.
- Treat long dermatology waits as a reason to strengthen primary-care eczema management, not defer it.
Evidence boundary
SourcedPatient testimonyCitation requiredCampaign ask
Published sources carry clinical and policy claims. Testimony shows lived experience. Unresolved material remains labelled Citation required.
What the campaign is not claiming
- It is not a treatment guide or medical advice service.
- It is not recommending named products, probiotics, ingredients, or routines.
- It is not claiming expensive products are automatically better.
- It is not treating patient testimony as clinical proof.
Contact
Email [email protected] for policy, evidence, media, charity, NHS stakeholder, or accessibility enquiries.
Constituency relevance
Why constituents may raise this.
Patients may be able to access prescriptions but still be left without a usable or tolerable routine.
Prescription access is not the whole issue
The policy question is whether the available option is clinically suitable and actually used.
Read the problemThe cost frame may be incomplete
Unit product cost should be tested against repeat demand, escalation, referral pressure, and self-funded care.
Read the evidence briefThe ask is practical
Documented first-line failure should trigger a clearer route to clinically suitable alternatives. This is a campaign recommendation based on sourced prescribing principles and citation-required pathway evidence.
See policy asksQuestions to ask
Questions MPs can put to NHS or policy bodies.
These are designed to open scrutiny without overstating the evidence.
- How is NHS eczema prescribing assessed beyond unit product cost?
- What route exists when first-line emollients have repeatedly failed or are not tolerated?
- Are local formularies reviewed for patients with documented need?
- How are long dermatology waits accounted for in primary-care eczema management?
- Is NHS England or NICE reviewing whether current emollient guidance gives GPs enough flexibility?
Evidence boundaries
What can and cannot be claimed now.
The campaign can describe the policy question and evidence gaps. It should not overstate scale, causation, or product effectiveness.
Published guidance, policy, official data, or peer-reviewed evidence carries the claim.
Lived experience shows how pathways can break down, but it is not treated as clinical proof.
Important claims remain clearly marked until the source trail is verified.
Next step
Use the campaign as a policy briefing, not a treatment guide.
MPs and offices can ask how documented first-line failure is handled and how total eczema care cost is measured.